Contemporary radiotherapy: present and future

RA Chandra, FK Keane, FEM Voncken, CR Thomas - The Lancet, 2021 - thelancet.com
Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …

Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis

EJ Lehrer, R Singh, M Wang, VM Chinchilli… - JAMA …, 2021 - jamanetwork.com
Importance The oligometastatic paradigm postulates that patients with a limited number of
metastases can be treated with ablative local therapy to each site of disease with curative …

Management of salivary gland malignancy: ASCO guideline

JL Geiger, N Ismaila, B Beadle, JJ Caudell… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To provide evidence-based recommendations for practicing physicians and
other healthcare providers on the management of salivary gland malignancy. METHODS …

[HTML][HTML] Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

A Krämer, T Bochtler, C Pauli, G Baciarello… - Annals of …, 2023 - annalsofoncology.org
CUP accounts for< 5% of cancers but, because of its high mortality rate, its relative
contribution to cancer deaths is higher. 1 The incidence of CUP has been declining …

[HTML][HTML] The abscopal effect: a review of pre-clinical and clinical advances

JR Janopaul-Naylor, Y Shen, DC Qian… - International journal of …, 2021 - mdpi.com
Radiotherapy has been used for more than a hundred years to cure or locally control tumors.
Regression of tumors outside of the irradiated field was occasionally observed and is known …

Appropriate use criteria for prostate-specific membrane antigen PET imaging

H Jadvar, J Calais, S Fanti, F Feng… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Prostate cancer is the most common cancer diagnosis in men in the United States and a
leading cause of cancer-related morbidity and mortality (1). It can exist along a wide …

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer …

CJ Tsai, JT Yang, N Shaverdian, J Patel, AF Shepherd… - The Lancet, 2024 - thelancet.com
Background Most patients with metastatic cancer eventually develop resistance to systemic
therapy, with some having limited disease progression (ie, oligoprogression). We aimed to …

Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial

M Spaas, N Sundahl, V Kruse, S Rottey… - JAMA …, 2023 - jamanetwork.com
Importance Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1
(PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of …

The oligometastatic spectrum in the era of improved detection and modern systemic therapy

RR Katipally, SP Pitroda, A Juloori… - Nature Reviews …, 2022 - nature.com
Metastases remain the leading cause of cancer-related mortality. The oligometastasis
hypothesis postulates that a spectrum of metastatic spread exists and that some patients …

ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases

J van der Velden, J Willmann, M Spałek… - Radiotherapy and …, 2022 - Elsevier
After liver and lungs, bone is the third most common metastatic site (Nystrom et al., 1977).
Almost all malignancies can metastasize to the skeleton but 80% of bone metastases …